(AMRN) Amarin Corporation plc Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(AMRN) Amarin Corporation plc Complete Analysis Pack
Amarin’s Business Model Blueprint: Fast, Clear Strategic Insights
Unlock the full strategic blueprint behind Amarin Corporation plc’s business model. This concise Business Model Canvas highlights how the company creates value, serves its target markets, and navigates a competitive biopharma landscape. Ideal for investors, analysts, and strategists, the full version offers deeper insights you can use right away.
Partnerships
Mochida Pharmaceutical Co., Ltd.
Amarin partners with Mochida Pharmaceutical Co., Ltd. to develop drug products and new indications from Vascepa’s active ingredient, icosapent ethyl. The tie-up supports pipeline growth in omega-3 acid and eicosapentaenoic acid, building on Vascepa’s approved 4 g/day dose and Amarin’s focus on expanding beyond its core cardiovascular market.
Wholesale distributors
Amarin Corporation plc relies on wholesale distributors as a core route to move VASCEPA into the market at scale, making them a key link between manufacturing and pharmacies. This channel helps Amarin reach prescription volumes efficiently and keeps product flowing through the U.S. supply chain.
Specialty pharmacy providers
Specialty pharmacy providers are a key part of Amarin Corporation plc’s delivery chain for VASCEPA, the branded cardiovascular therapy used by adults with high triglycerides. They manage prescription fill, prior-authorization support, and repeat dispensing, which helps keep long-term therapy moving for patients who need ongoing treatment.
Prescribing healthcare professionals
VASCEPA is prescription only, so prescribing healthcare professionals are the gatekeepers to patient access and the link between Amarin Corporation plc and the target treatment population. In the United States, Amarin’s VASCEPA label covers 4 g per day, making physician diagnosis, prescribing, and follow-up central to use.
- Prescription-only access
- Physicians drive patient reach
- Connects product to treatment population
International market stakeholders
Amarin Corporation plc relies on international market stakeholders across 5 active regions: the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Local commercial partners, payers, and healthcare providers help Amarin navigate pricing, reimbursement, and regulatory access, so cross-border commercialization stays workable.
- 5-country operating footprint
- Local access and reimbursement support
- Healthcare ecosystem ties by market
Amarin’s Partner Network Powers VASCEPA’s U.S. and Global Reach
Amarin Corporation plc’s key partnerships center on Mochida Pharmaceutical Co., Ltd. for icosapent ethyl development, plus wholesale distributors, specialty pharmacies, and prescribers that keep VASCEPA moving through the U.S. chain. Its international access network spans 5 active regions, supporting reimbursement and local launch work.
| Partner | Role |
|---|---|
| Mochida | Pipeline |
| Distributors | Supply |
| Specialty pharmacies | Fill |
| Physicians | Prescribe |
| 5 regions | Access |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Amarin Corporation plc, mapping its 9 key blocks and strategic fit.
Customizable Excel Spreadsheet
Quickly spot Amarin Corporation plc’s business model pain points with a one-page, easy-to-edit canvas.
Reference Sources
Provides a concise source trail for Amarin Corporation plc, strengthening credibility and speeding smarter due diligence.
Activities
Research and development
Amarin Corporation plc keeps research and development centered on cardiovascular disease, with omega-3 based therapies as the core platform. Its R&D work supports growth beyond VASCEPA, which has 2 U.S. indications, and builds the pipeline for new uses and future products.
Drug commercialization
Amarin Corporation plc commercializes VASCEPA, its flagship prescription product, across the U.S. and other regions, turning clinical proof into payer access, prescriptions, and sales. In 2025, this remained the core revenue driver as the company focused on market reach, physician adoption, and regional execution.
Clinical and indication expansion
Amarin kept pushing clinical and indication expansion around icosapent ethyl in 2025, using the same active molecule to extend Vascepa’s life cycle beyond its core use. The move is anchored by REDUCE-IT, which enrolled 8,179 patients and cut major cardiovascular events by 25%, supporting broader label and market opportunities.
Supply and distribution management
Amarin Corporation plc manages supply and distribution through wholesale channels and specialty pharmacies, making product flow a core operating task. This keeps VASCEPA available to patients and providers, and it matters even more as the company works through a much smaller revenue base after generic pressure.
In practice, tight inventory control, order fulfillment, and partner coordination help protect access and reduce stock gaps across the channel.
- Wholesale channel execution
- Specialty pharmacy fulfillment
- Inventory and product flow control
- Patient and provider access support
Regional operations
Amarin Corporation plc runs regional operations across the United States, Germany, Canada, Lebanon, and the United Arab Emirates, so execution has to match each market’s rules, reimbursement, and selling channels. One global plan does not work here; local coordination drives access, compliance, and sales performance.
- Five named markets need local execution
- US and Europe need different access paths
- Compliance and supply must stay local-fit
Amarin’s VASCEPA: 8,179-Patient Study Backs 25% Event Reduction
Amarin Corporation plc’s key activities center on VASCEPA research, label expansion, and commercialization, with 2 U.S. indications still anchoring the business. REDUCE-IT enrolled 8,179 patients and showed a 25% drop in major cardiovascular events, which supports ongoing clinical work.
| Key activity | Latest data |
|---|---|
| Clinical evidence | 8,179 patients |
| Event reduction | 25% |
| U.S. indications | 2 |
What You See Is What You Get
Business Model Canvas
This preview is a real excerpt from the Amarin Corporation plc Business Model Canvas, not a sample or mockup. When you purchase, you’ll receive the exact same professionally formatted document you see here, with the full content included. No changes, no surprises—just the same ready-to-use file for editing, presenting, or sharing.
Resources
VASCEPA brand
VASCEPA is Amarin Corporation plc’s flagship brand and its main market-facing asset, built around icosapent ethyl 4 g/day for cardiovascular risk and triglyceride management. Its core proof point is REDUCE-IT, which enrolled 8,179 patients and supports the brand’s clinical value in a large, high-risk population.
Omega-3 acid API
Amarin Corporation plc’s key resource is its omega-3 acid API, centered on eicosapentaenoic acid, the chemistry behind VASCEPA’s 1 g capsules and 2 g twice-daily dosing. This API supports current products and future pipeline work, so it sits at the core of Amarin Corporation plc’s heart-risk strategy and commercial model.
Prescription-only product status
VASCEPA is sold only by prescription, so Amarin Corporation plc keeps use under physician oversight for defined patient groups and channels demand through regulated healthcare systems. In 2025, Amarin reported $214.2 million in net product sales, showing how Rx-only status supports controlled access and commercial tracking.
International operating footprint
Amarin Corporation plc’s international operating footprint spans the United States, Germany, Canada, Lebanon, and the United Arab Emirates, giving it a five-country commercial base. That reach is a key resource because it broadens access to patients and payers while reducing reliance on any single market.
- Five-country operating footprint
- Supports geographic reach
- Diversifies market risk
Dublin headquarters
Amarin Corporation plc’s Dublin, Ireland headquarters is the group’s control point for corporate governance and administrative coordination, supporting global oversight from one base. As of its latest public filings, Dublin remains the company’s main center for managing operations, finance, and compliance across markets.
- Dublin HQ centralizes control
- Supports global management
- Coordinates admin and compliance
VASCEPA Drives Amarin’s 2025 Growth Across 5 Markets
Amarin Corporation plc’s key resources are VASCEPA, the EPA-based API, and its regulated commercial footprint across 5 countries. In 2025, Amarin Corporation plc generated $214.2 million in net product sales, and REDUCE-IT enrolled 8,179 patients, supporting the brand’s clinical and commercial base.
| Key resource | 2025/2026 data |
|---|---|
| VASCEPA sales | $214.2 million |
| REDUCE-IT patients | 8,179 |
| Operating countries | 5 |
Value Propositions
Triglyceride reduction support
VASCEPA is Amarin Corporation plc’s core triglyceride-lowering offer: used as an adjunct to diet, it is indicated to reduce elevated triglyceride levels in adults with severe hypertriglyceridemia (≥500 mg/dL). This clear clinical use case is the main value proposition behind Amarin’s lipoprotein franchise.
Cardiovascular therapy focus
Amarin’s value proposition is tightly centered on cardiovascular care, with VASCEPA as its core therapy for patients at elevated cardiovascular risk. In 2024, the Company reported net revenue of about $220 million, showing that its product strategy stays concentrated in one disease area and supports a clear, specialist medical position.
Prescription-only medical treatment
Amarin Corporation plc sells VASCEPA as a prescription-only 4 g/day therapy for adults, which keeps use under physician oversight and supports ongoing patient monitoring. That model fits its FDA-approved CV-risk indication in patients with triglycerides of 150 mg/dL or higher and aligns treatment with controlled, clinically guided use.
Omega-3 based formulation
Amarin Corporation plc’s omega-3 formulation centers on icosapent ethyl, a purified eicosapentaenoic acid (EPA) therapy, so it sits apart from over-the-counter fish oil supplements. Its clinical edge comes from REDUCE-IT, which enrolled 8,179 patients and showed a 25% relative risk reduction in major cardiovascular events.
- Purified EPA, not a supplement blend
- Backed by 8,179-patient REDUCE-IT data
- 25% lower major CV event risk
Expansion potential from core API
Amarin Corporation plc is extending the Vascepa API beyond its original label through new products and new indications with Mochida, which can widen the molecule’s use cases and support longer product life. With 2 approved U.S. indications already in place, this API platform gives Amarin Corporation plc a clearer path to add value after the first launch cycle.
- 2 approved U.S. indications
- New products from the same API
- Longer molecule value life
Amarin’s VASCEPA: Proven CV Risk Reduction With $220M in 2024 Revenue
Amarin Corporation plc’s value proposition is a prescription, purified EPA therapy that targets high triglycerides and cardiovascular risk, not an OTC supplement. VASCEPA’s clinical edge comes from REDUCE-IT: 8,179 patients, 25% lower major CV event risk, and 2 approved U.S. indications. 2024 net revenue was about $220 million.
| Key point | Data |
|---|---|
| Clinical proof | REDUCE-IT, 8,179 patients |
| Risk reduction | 25% lower major CV events |
| Commercial scale | 2024 net revenue about $220 million |
Customer Relationships
Physician-led prescribing
VASCEPA is prescription-only, so Amarin Corporation plc’s customer relationship runs through physicians, not end users. In 2025, the 4 g/day therapy still depended on clinician-led risk assessment and prescribing, keeping clinical judgment at the center of access and adherence.
Specialty pharmacy coordination
Specialty pharmacy coordination helps Amarin Corporation plc keep VASCEPA moving through a managed dispensing channel, with specialty pharmacies handling enrollment, access checks, and shipment for patients with cardiovascular risk. That matters because heart disease still causes about 1 in 5 U.S. deaths, so tight pharmacy routing helps link therapy to a large, high-need patient base.
Wholesale account management
Amarin Corporation plc depends on wholesale account management to keep VASCEPA moving through pharmacy and payer channels, so product stays available across the healthcare system. Tight account control supports steady supply, better fill rates, and fewer gaps for patients and providers.
Ongoing treatment usage
VASCEPA is taken as an adjunct to diet, so Amarin Corporation plc’s customer link is driven by repeat prescriptions and long-term disease control, not one-off sales. The 4 g/day regimen and the 8,179-patient REDUCE-IT base support ongoing use in patients who need chronic triglyceride and cardiovascular risk management.
- Repeat prescriptions, not single use
- Adjunct to diet, long-term care
- Chronic CV-risk management supports retention
Regional market support
Amarin’s regional market support helps keep healthcare customers and partners aligned across the countries where it sells Vascepa, so local teams can handle market access, logistics, and compliance fast. That matters because regional coordination keeps service steady when rules, reimbursement, and channel needs differ by market.
- Local teams support each country.
- Helps protect continuity of care.
- Fits Amarin’s multi-country sales model.
VASCEPA’s physician-led network drives chronic repeat use
Amarin Corporation plc’s customer relationships are physician-led and run through specialty pharmacies and wholesalers, because VASCEPA is prescription-only and used for long-term cardiovascular risk care. In 2025, the 4 g/day regimen and the 8,179-patient REDUCE-IT evidence base supported repeat prescribing and adherence.
| Channel | 2025-2026 cue |
|---|---|
| Physicians | Prescription-led |
| Specialty pharmacy | Access and shipment |
| Patients | 4 g/day chronic use |
Channels
Wholesale channels
Wholesale channels are Amarin Corporation plc’s main route to market, moving Vascepa from manufacturing into U.S. healthcare supply networks through large distributors such as McKesson, Cencora, and Cardinal Health. In the U.S., these three wholesalers handle roughly 90% of drug distribution, so this channel is core to reach.
Specialty pharmacy providers
Specialty pharmacy providers are a core dispensing channel for Amarin Corporation plc because VASCEPA is prescription-only and needs eligibility checks before fill. They help route therapy to the right patients, support adherence, and fit a controlled channel model; Amarin reported $23.0 million in net product revenue in 2024.
Prescribing clinicians
Prescribing clinicians are Amarin Corporation plc’s gatekeeper channel: they diagnose, write the prescription, and start access to Vascepa, which is prescription only. This channel links clinical diagnosis to dispensing, so if prescribers do not adopt, no downstream pharmacy fill happens.
International markets
Amarin Corporation plc uses international markets as commercialization channels in the United States, Germany, Canada, Lebanon, and the United Arab Emirates, giving it 5 active geographies to widen reach for Vascepa. This multi-country setup helps Amarin sell beyond one market and supports broader access to prescription revenues.
- 5 commercialization markets
- United States plus 4 international geographies
- Extends market reach
Partner-led product development
Amarin Corporation plc’s Mochida collaboration helps advance Vascepa-derived products, giving Amarin a second path to growth beyond U.S. Vascepa sales. In FY2024, Amarin reported net revenue of $200.8 million, so partner-led development matters as a way to extend the product story beyond one indication and one market.
- Supports Vascepa-derived pipeline work
- Creates another route to market expansion
- Reduces reliance on one indication
Amarin’s VASCEPA Distribution Power in 5 Markets
Amarin Corporation plc’s channels run through U.S. wholesalers, specialty pharmacies, prescribers, and five commercialization markets, with McKesson, Cencora, and Cardinal Health covering about 90% of drug distribution. This setup matters because VASCEPA is prescription-only, and Amarin reported 2024 net product revenue of $23.0 million and total net revenue of $200.8 million.
| Channel | Value |
|---|---|
| Wholesalers | ~90% U.S. drug distribution |
| Commercial markets | 5 geographies |
| 2024 net product revenue | $23.0 million |
| 2024 net revenue | $200.8 million |
Customer Segments
Adults with severe hypertriglyceridemia
Adults with severe hypertriglyceridemia are Amarin Corporation plc’s clearest customer segment because VASCEPA is indicated for adults with triglycerides of 500 mg/dL or higher. This group is the core fit for pancreatitis-risk management, and the label keeps the therapy focused on a clearly defined, high-need population.
Cardiovascular disease patients
Amarin Corporation plc serves cardiovascular disease patients as its core customer segment, with therapies built for lipid management and risk reduction in this disease area. Cardiovascular disease causes about 17.9 million deaths a year worldwide, so the addressable patient pool remains large and clinically urgent.
Prescribing physicians
Prescribing physicians are the gatekeepers for Amarin Corporation plc because its omega-3 therapy is prescription only, so they decide eligibility, start treatment, and keep patients on therapy. In practice, adoption by these doctors drives every fill: Amarin’s U.S. business still centers on one branded product, VASCEPA, approved for 2 labeled uses.
Specialty pharmacies
Specialty pharmacies are a direct commercial channel for Amarin Corporation plc: they dispense VASCEPA and handle fulfillment, prior authorizations, and refill support. They sit between Amarin Corporation plc and patients, so their execution affects access, speed, and persistence in therapy.
- Direct dispensing channel
- Supports fulfillment and access
- Key intermediary in the chain
Wholesalers
Wholesalers are a key customer segment for Amarin Corporation plc because they move product through the supply chain and give Amarin access to pharmacies and other downstream buyers. In Amarin Corporation plc’s 2025 filings, this channel remained central to market reach, since broad wholesale coverage is what turns prescriptions into filled orders.
- Moves product fast
- Extends market access
- Supports pharmacy fulfillment
Amarin’s Growth Depends on Doctor Adoption and Channel Execution
Amarin Corporation plc mainly serves adults with severe hypertriglyceridemia, defined on VASCEPA’s label as triglycerides of 500 mg/dL or higher, plus cardiovascular-risk patients in its approved lipid-management use. Prescribing physicians, specialty pharmacies, and wholesalers are the key buying and access points, so doctor adoption and channel execution drive every fill.
| Segment | Role | Key fact |
|---|---|---|
| Patients | End users | 2 labeled uses |
| Physicians | Prescribers | Prescription only |
| Pharmacies | Dispense | Fulfillment and refills |
| Wholesalers | Distribute | Supply-chain access |
Cost Structure
Research and development spend
Amarin Corporation plc is still R&D-led, and cardiovascular drug work needs steady science spend, so this stays a fixed cost. In fiscal 2025, research and development was about $20 million, roughly 11% of revenue, showing how heavily the Company depends on long-cycle product work.
Clinical and indication development
Amarin Corporation plc is advancing new indications from the Vascepa API, so clinical planning, trial ops, and regulatory work keep adding to development cost load. In 2025, that spend stayed tied to R&D execution rather than scale economics, because each new indication needs separate clinical evidence and filing work.
Commercialization expense
Commercialization expense is a central cost for Amarin Corporation plc because VASCEPA has to be sold through doctors, payers, and pharmacy channels, so market access and sales support matter. In the latest filings, this spend sits inside SG&A and stays material versus revenue, making it a key drag on operating leverage.
Distribution and supply chain costs
Amarin Corporation plc moves VASCEPA/VAZKEPA through wholesale and specialty pharmacy channels, so inventory control, cold-chain-free delivery, and order servicing add recurring logistics cost. In 2024, product revenue was $208.5 million, and the company still reported a net loss of $145.0 million, showing how global distribution overhead can weigh on margins.
- Wholesale and specialty pharmacy routing
- Inventory and delivery drive logistics expense
- Global regions add process complexity
International corporate overhead
Amarin Corporation plc’s international footprint means international corporate overhead stays heavy: legal, compliance, tax, and management teams must support sales and filings across multiple markets from Dublin. The Dublin HQ anchors this setup, but it also adds fixed cross-border costs that rise when the company expands or changes regulatory rules.
- Dublin HQ supports global control.
- Multi-country work lifts fixed costs.
- Compliance and legal spend stays structural.
Amarin’s R&D-heavy cost base keeps operating leverage weak
Amarin Corporation plc’s cost base is still dominated by R&D, commercial support, and global SG&A. In fiscal 2025, research and development was about $20 million, or roughly 11% of revenue, while product revenue stayed under pressure, so operating leverage remained weak.
| Cost driver | 2025 |
|---|---|
| R&D | ~$20m |
| R&D as % of revenue | ~11% |
| Product revenue | 2024: $208.5m |
Revenue Streams
VASCEPA prescription sales
VASCEPA is Amarin Corporation plc’s flagship prescription-only revenue stream, and sales rise with patient demand plus physician prescribing. In 2024, Amarin reported net revenues of $221.7 million, with VASCEPA driving almost all of it, so each refill and new script matters.
Wholesale sales
Amarin Corporation plc’s wholesale sales channel is its core revenue stream, with revenue booked when product ships into distributors rather than at the patient sale. This is the standard pharma model: wholesalers handle inventory, and Amarin converts prescription demand into product movement and reported net product revenue.
Specialty pharmacy sales
Specialty pharmacies give Amarin Corporation plc a second direct revenue path by dispensing prescription therapies like VASCEPA, so the company can capture value beyond retail and hospital channels. In Amarin Corporation plc's latest reported year, net product revenue was driven mainly by prescription demand, making this channel important for repeat fills and tighter payer control.
International market sales
Amarin Corporation plc sells in the United States, Germany, Canada, Lebanon, and the United Arab Emirates, so international market sales spread revenue across several geographies instead of one country. In the latest reported period, U.S. net product sales were $18.5 million, while Europe and the rest of the world added lower, but diversified, regional revenue.
- Five-country reach reduces single-market risk
- U.S. still drives most sales
- Non-U.S. markets add diversification
New product and indication commercialization
Amarin and Mochida are developing new products and indications from the Vascepa API, which can add royalties, supply revenue, and product sales beyond the original use. This matters because Vascepa is already a branded icosapent ethyl product with one active API, so each approved expansion can widen monetization without starting from zero.
- New indications can lift lifetime revenue.
- API reuse lowers development friction.
- Partnerships can split commercialization risk.
Amarin’s Revenue Still Rides on VASCEPA
Amarin Corporation plc’s revenue is still almost entirely VASCEPA-driven: 2024 net revenue was $221.7 million, with U.S. demand the main engine. Wholesale and specialty-pharmacy shipments book revenue, while international sales and API partnerships add smaller, diversified lines.
| Stream | 2024 value |
|---|---|
| VASCEPA net revenue | $221.7M |
| U.S. net product sales | $18.5M |
| International markets | Lower, diversified |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.